UNIVERSITÀ
DI SIENA
1240

Prof. Giuseppe Campiani, PhD

Professore Ordinario di Chimica Farmaceutica
Professor of Medicinal Chemistry

03/D FARMACEUTICO, TECNOLOGICO, ALIMENTARE
03/D1 CHIMICA E TECNOLOGIE FARMACEUTICHE, TOSSICOLOGICHE E NUTRACEUTICO ALIMENTARI
CHIM/08 Chimica Farmaceutica

Nome	**GIUSEPPE CAMPIANI**
Telefono	
E-mail	
PEC	
Nazionalita'	Italiana
Data di nascita	
Residenza	

ESPERIENZA PROFESSIONALE

• Data	**2022-ad oggi**
• Istituzione	**Isfahan University of Medical Sciences - IRAN**
• Posizione	**Adjunct Professor of Medicinal Chemistry**
• Data	**2002 – ad oggi**
• Istituzione	**Universita' di Siena**
• Posizione	**Professore Ordinario di Chimica Farmaceutica-03/D1-SSD CHIM08**
• Data	**1998 – 2001**
• Istituzione	**Universita' di Salerno**
• Posizione	**Professore Associato di Chimica Farmaceutica-SSD CHIM08**
• Data	**1990 – 1998**
• Istituzione	**Universita' di Siena**
• Posizione	**Ricercatore Universitario di Chimica Farmaceutica-SSD CHIM08**
• Data	**2000-2001**
• Istituzione	**Trinity College in Dublin, Dipartimento di Biochimica**
• Posizione	**Visiting Professor**
• Data	**1994-1995**
• Istituzione	**Columbia University in the City of New York-NY**
• Posizione	**Visiting Scientist**
• Data	**1992-1993**

• Istituzione	**Mayo Clinic Jacksonville-Florida**
• Posizione	**Postdoctoral Fellow**
• Data	**1985 – 1988**
• Istituzione	**Universita' di Siena**
• Posizione	**Dottorato di Ricerca in Scienze Farmaceutiche-SSD CHIM08**

ATTIVITA' ISTITUZIONALI

• Data	**2018-2021**
• Istituzione	**MIUR**
• Posizione	**Membro della Commissione Abilitazione Scientifica Nazionale SC 03/D1**
• Data	**2017**
• Istituzione	**MIUR**
• Posizione	**Comitato Selezione Progetti FARE**
• Data	**2011 – 2016**
• Istituzione	**Universita' di Siena**
• Posizione	**Delegato del Rettore alla Cooperazione Internazionale allo Sviluppo**
• Data	**2014-2017**
• Istituzione	**C.R.U.I. – Conferenza dei Rettori delle Universita' Italiane, Roma**
• Posizione	**Coordinamento CRUI per la Cooperazione Internazionale Universitaria e Referente CRUI per i Progetti di Cooperazione Internazionale P.R.I.M.A. – MIUR/EU e UNSDSN - MED**
• Data	**2008 - 2012**
• Istituzione	**Universita' di Siena**
• Posizione	**Direttore del Dipartimento Farmaco Chimico Tecnologico – Universita di Siena**
• Data	**2010 – ad oggi**
• Istituzione	**CIRM – Centro Italiano per la Ricerca sulla Malaria**
• Posizione	**Fondatore**
• Data	**2003 – 2016**
• Istituzione	**Centro di Ricerca Europeo per la Progettazione e lo Sviluppo di Farmaci – Universita' di Siena**
• Posizione	**Direttore**
• Data	**2011 – 2016**
• Istituzione	**SIENA AGRIFOOD sostenibilita' alimentare, sicurezza alimentare ed agricoltura sostenibile**
Posizione	**Fondatore e membro**
• Data	**2012 – 2015**
• Istituzione	**Universita' di Siena**
• Posizione	**Presidente Corso di Laurea Magistrale in Farmacia**

CAPACITA' PERSONALI E COMPETENZE

LINGUA MADRE	**ITALIANO**
ALTRE LINGUE	**English**
• Lettura	ottima
• Scrittura	ottima
• Capacita' verbali	ottima

QUALIFICAZIONE PROFESSIONALE

AMBITO/ESPERTO LIFE SCIENCES, RICERCA DI BASE, RICERCA INDUSTRIALE E KEY ENABLING TECHNOLOGIES

DOCENZA ED ATTIVITA' DI RICERCA

1990-TO DATE: CHIMICA FARMACEUTICA E DRUG DISCOVERY AND DEVELOPMENT (R&D)

INCARICHI VALUTAZIONE PROGETTI INDUSTRIALI COFINANZIATI DA RISORSE EUROPEE

DA 15 ANNI IL PROF. CAMPIANI SVOLGE ATTIVITA' DI VALUTAZIONE DI PROGETTI PER CONTO DI MISE, MIUR, REGIONI, UNIVERSITA' E ALTRE ORGANIZZAZIONI INTERNAZIONALI

- 2023-2025 Nominato membro della Commissione Tecnica di Valutazione "Scienze della Vita" DD n° G05512 prop. N° 15561-Regione Lazio-Lazioinnova

- 2023-2024 Nominato Esperto Tecnico Scientifico InnovaPUGLIA – Regione Puglia Bando INNOAID Cod. Comm. RP2317

- 2008-to date Iscritto all' Albo degli Esperti Innovazione Tecnologica del Ministero Sviluppo Economico

- 2020-2023 Esperto valutatore Progetti MiSe - Medio Credito Centrale

- 2021 Esperto Tecnico Scientifico – Progetti Strategici L.R. 13/2008 LazioInnova Regione Lazio Cod Commessa SF2I003 CIG Z5F3060IFC

- 2019-2020 Esperto Tecnico Scientifico Progetti INNOIAID Regione Puglia

- 2018 Esperto Tecnico Scientifico Progetti realizzazione di studi di fattibilita' (Fase 1) e progetti di trasferimento tecnologico (Fase2) coerenti con la RIS3 – Regione Campania – Incarico n. 262/2018

- 2020-2022 Invitalia - Esperto tecnico scientifico contratto JN000/2015E003INV/2020/47 per consulenza ed assistenza specialistica

- 2018-2020 Invitalia - Esperto tecnico scientifico contratto JN000/2015E003INV/2018/105 per consulenza ed assistenza specialistica

- 2018 Esperto tecnico scientifico Regione Campania POR FESR 2014/2020 Piattaforme Tecnologiche Oncologiche

- 2018-2021 Esperto Tecnico Scientifico Regione Campania POR FESR 2014/2020 Progetti industriali di innovazione tecnologica: creazione e consolidamento di start-up innovative: "CAMPANIA START UP INNOVATIVA", incarico N° 66 e 122

- 2017-2018 Esperto di Ricerca e Innovazione Tecnologica – Membro Comitato Valutazione – POR FESR Lazio 2014-2020 – KETS, LazioInnova – Regione Lazio Contratto n° SF I7012 Prot. 23253

- 2018 Esperto Tecnico Scientifico POR FESR Lazio 2014-2020 – Progetti Strategici, LazioInnova – Regione Lazio Contr Coll Prof n° SF I18012_O CIG Z1B22A973B

- 2015-2018 Invitalia - Esperto tecnico scientifico contratto JN000/2013E0022NAZ.LE/2015/53 per consulenza ed assistenza specialistica

- 2010-2018 Iscritto all' Albo degli Esperti del MIUR per la valutazione dei Grandi Progetti Strategici – GPS e PON/POR e REPRISE

- 2017 Membro della Commissione Selezione dei Progetti FARE – MIUR

- 2016-2021 Esperto iscritto al Registro Commissione Europea – SCHEER-Salute 1504770982260-5144.

- dal 2010 iscritto all' albo degli esperti in Cooperazione Internazionale dell' OICS, Sez. 3 e 4

- Iscritto nelle liste di esperti EU per i Progetti Europei – FP7, H2020 in campo farmaceutico, biotech e agroalimentare Expert ID EX2013D140191

- 2015-2020 esperto in ambito biotecnologico e farmaceutico Puglia Sviluppo-Regione Puglia- (P.I.A.)

- 2017 Consulente Esperto Innovazione Tecnologica Comitato Selezione Progetti KET-Innonetwork, INNOVAPUGLIA - Regione Puglia Contratto Consulenza n. 16/2017

- 2017 Progetti MIUR FIRB/SIR: nominato esperto tecnico scientifico dal Comitato Nazionale Garanti della Ricerca - CNGR

- 2015 Selezionato come esperto in tematiche di Life Sciences da UNIMORE

- 2018-2019 Valutatore Progetti Ricerca e Innovazione CE18 - Innovation biomédicale ANR – Agence Nationale de la Recherche-FRANCIA

COORDINAMENTO PROGETTI SCIENTIFICI

COORDINATORE/RESPONSABILE UO PROGETTI DI RILEVANTE INTERESSE NAZIONALE ED EU

RESPONSABILITA' DI STUDI E RICERCHE SCIENTIFICHE AFFIDATI DA QUALIFICATE ISTITUZIONI NAZIONALI ED INTERNAZIONALI:

- PRIN 2022 – PROT. 2022944N8J COORDINATORE NAZIONALE – NOVEL EPIGENETIC MODIFIERS FOR A MUTATION-INDEPENDENT PHARMACOLOGICAL APPROACH TO EXTEND PHOTORECEPTOR SURVIVAL IN RP

- PRIN 2015 – PROT. 20154JRJPP COORDINATORE NAZIONALE TOWARDS MULTI-STAGE DRUGS TO FIGHT POVERTY RELATED AND NEGLECTED PARASITIC DISEASES: SYNTHETIC AND NATURAL COMPOUNDS DIRECTED AGAINST LEISHMANIA, SCHISTOSOMA LIFE STAGES AND ASSESSMENT OF THEIR MECHANISMS OF ACTION.

- EU H2020 2016: *TRACT* 721906 ITN TREATMENT OF RARE CANCERS – RESEARCH COORDINATOR

- MAECI 2014 LUTTE CONTRE LE PALUDISME AU BURKINA FASO: FORMATION ET RECHERCHE EN PALUDOLOGIE – MEMBRO C.O.S. 2015 - 2020

- PRIN 2004 – PROT. 2004032851_003 ASPETTI MOLECOLARI DI PATOLOGIE CONFORMAZIONALI PROTEICHE. PROGETTAZIONE E SINTESI DI AGENTI ANTIAGGREGANTI AD ATTIVITA' TERAPEUTICA NONCHÈ PER APPLICAZIONI IN DIAGNOSTICA.

- PRIN 2006 -PROT.2006033492_003, "SYNTHETIC AND COMPUTATIONAL STUDIES FOR THE DEFINITION OF THE ROLE OF METAL IONS IN THE UBIQUITINE-MEDIATED DEGRADATION PROCESSES OF MISFOLDED PROTEINS IN ALZHEIMER DISEASE"

- PRIN 2008 – PROT. 20088SPEFN_005 PROGETTAZIONE E SINTESI DI MODULATORI DI FAAH E MAGL

- PRIN 2010 -PROT.2010M2JARJ - 008 IONI METALLICI NELLE PATOLOGIE DA INVECCHIAMENTO: INTERPLAY TRA METALLOSTASI E PROTEOSTASI NELLA NEURODEGENERAZIONE

- MPS 2007 - RIF.29815 "SVILUPPO DI NUOVI ANTIMALARICI" GRANTED BY FONDAZIONE MPS IN 2008

RESPONSABILITA' IN PROGETTI EUROPEI

- EU H2020 2016: *TRACT* 721906 ITN TREATMENT OF RARE CANCERS – RESEARCH COORDINATOR
- ANTIMAL LSHP-CT-2005-018834 "DEVELOPMENT OF NEW DRUGS FOR THE TREATMENT OF MALARIA" GRANTED BY EU-FP6 IN 2005
- SPIDERA FOR LIFE LSH-2005-3-1-037207 "SPEEDING COLLABORATIONS IN THE LIFE
- SCIENCE AND HEALTH DOMAIN OF THE EUROPEAN RESEARCH AREA AND BEYOND" GRANTED BY EU-FP6 SSA 2007.2009
- SME BIO POWER FP7-201119 "EMPOWERING BIOMEDICAL AND BIOENGINEERING SMES TO PROMOTE PARTICIPATION IN FP7 PROJECTS" GRANTED BY EU-FP7 SSA 2008-2011
- INTERMALTRAINING – 2009 FP7 ITN MARIE CURIE ACTION – 215281-1 "INTERVENTION STRATEGIES AGAINST MALARIA"
- EUROPEAN GRADUATE SCHOOL OF MALARIA 2006 LSHP-CT-2005-018834
- CONVENZIONE TRA UNIVERSITA' DI SIENA E GIUSEPPE CAMPIANI PROT 1638/1999 E 2026/2000 PER ATTIVITA' DI RICERCA INERENTE IL BIORESEARCH IRELAND

RESPONSABILITA' SCIENTIFICA PROGETTI INDUSTRIALI E CONSULENZE

- SIGMA-TAU/UNISI "STUDIO DI POTENZIALI INIBITORI REVERSIBILI DI FAAH PROT. N° 3884 IN 2007
- SIGMA-TAU/UNISI "PROGETTAZIONE E SINTESI DI NUOVI INIBITORI DI FAAH PROT. N° 4697 IN 2008
- SIGMA-TAU/UNISI "INIBITORI DI FAAH PROT. N° 5113 / 2009
- SIGMA-TAU (IT)/UNISI "NUOVI ANTIPSICOTICI ATIPICI IN 2003 D R&S/03/C./81
- SIGMA-TAU (IT)/UNISI "SINTESI DI MOLECOLE A PROBABILE ATTIVITA' MGLU/D2 IN 2005-2006 D R&S/04/CR/77
- SIGMA-TAU (IT)/UNISI "SINTESI DI MOLECOLE AD ATTIVITA' AGONISTA SU RECETTORE MGLUR5 E ANTAGONISTA SUL D2 2007 PROT. N° 4351/2007
- SIGMA-TAU (IT)/UNISI "NUOVI ANTISCHIZOFRENICI AD ATTIVITA' AGONISTA PARZIALE SU RECETTORE MGLUR5 E ANTAGONISTA SUL D2 2007 PROT. N° 4802/2008
- SIGMA-TAU (IT)/UNISI "MNSNC SINTESI DI ANTAGONISTI D2, 5HT2 ANTIPSICOTICI ATIPICI IN 2001-2002 D R&S/00/CR/57
- SIGMA-TAU (IT)/UNISI "NUOVI ANTIPSICOTICI ATIPICI IN 2003 ACCORDO QUADRO PROT. N° 2891 DEL 2003
- SIGMA-TAU (IT)/UNISI "SINTESI DI NUOVE MOLECOLE AD ATTIVITA' ANTIPSICOTICA PER IL PROGETTO IDENTIFICAZIONE MOLECOLA DERIVATA DA ST1469 – SVILUPPO SINTESI SEMPLIFICATA PROT. 3187/2004
- SIGMA-TAU (IT)/UNISI "MNSNC SINTESI DI ANTAGONISTI D2, 5HT2 ANTIPSICOTICI ATIPICI IN 2000 D R&S/01/C./08
- SIGMA-TAU (IT)/UNISI "MNSNC SINTESI DI ANTAGONISTI D2, 5HT2 ANTIPSICOTICI ATIPICI IN 1998-1999 D R&S/98/CR/39
- SIGMA-TAU (IT)/UNISI CONTRATTO DI RICERCA: BREVETTAZIONE DI FARMACI ANTIPSICOTICI PROT. 1394 DEL1998
- SIGMA-TAU (IT)/UNISI "SINTESI DI MOLECOLE ORIGINALI CON AFFINITA' PER IL RECETTORE 5HT6 IN 1998, PROT. 1393
- SIGMA-TAU (IT)/UNISI "MNSNC SINTESI DI ANTAGONISTI 5HT6 IN 2000 D R&S/00/CR./05
- SIGMA-TAU (IT)/UNISI "STUDI SINTETICI PER MOLECOLE DI INTERESSE 1998 D R&S/98/CR./15
- SIGMA-TAU (IT)/UNISI "STUDI SINTETICI PER MOLECOLE DI INTERESSE 1998 D R&S/98/CR./17
- NEUROSEARCH (DK)/UNISI "SYNTHESIS OF COMPOUNDS FOR CALCIUM CHANNELS" IN 2002-2003 PROT. 2810 DEL 2002
- NEUROSEARCH (DK)/UNISI "GENERATING CHEMICAL ENTITIES SUITABLE FOR DEVELOPMENT AS A THERAPEUTIC TREATMENT OF PSYCHOSIS" IN 2004-2005 PROT 3361/299/2004
- NEUROSEARCH (DK)/UNISI "NEW THERAPEUTIC TOOLS FOR NEUROPSYCHIATRIC DISORDERS" IN 2005-2007 PROT. N° 3900
- NEUROSEARCH (DK)/UNISI "RESEARCH AGREEMENT IN 2008-2011
- INTERMUNE US/UNISI RESEARCH AGREEMENT FOR BINDER: DRUGS AGAINST HCV, 2005 PROT. N° 2769/2005

1. 2002-2008 CONTRATTO DI CONSULENZA CON SIGMA.TAU RIF ALSI/EP/FR – PC/NB/03- GB R&S/NB/ER CHIMICA DI NUOVI COMPOSTI PER AREE TERAPEUTICHE DI INTERESSE

2. 2002-2005 CONSULTANCY AGREEMENT WITH NEUROSEARCH AS AUT 14319 DEL 01-08-2002

3. 2006-2008 CONSULTANCY AGREEMENT WITH NEUROSEARCH – RINNOVO/RENEWAL

4. 2009-2011 CONSULTANCY AGREEMENT WITH NEUROSEARCH – RINNOVO/RENEWAL

RESPONSABILITA' SCIENTIFICA PROGETTI DI RICERCA FINANZIATI DA ENTI

- EPIGENETIC AND PROTEOMIC APPROACHES TOWARDS IPF - BANDO SALUTE REGIONE TOSCANA 2018 PROGETTO HIDE-IPF, DD 8245 DEL 26/05/2020 – COORDINATORE SCIENTIFICO 2020-2023
- DEVELOPMENT OF PERSONALIZED DIAGNOSIS AND INNOVATIVE THERAPIES FOR RESISTANT CLL - BANDO SALUTE REGIONE TOSCANA 2018 PROGETTO PRECISECLL, DD 975 DEL 16/01/2020
- DEVELOPMENT OF INNOVATIVE ANTITUMOR AGENTS – REGIONE TOSCANA BANDO SALUTE HEALTH 2010-CUP: B61J09000610007

- DEVELOPMENT OF INNOVATIVE PEPTIDIC ANTICANCER AGENTS – ISTITUTO TOSCANO TUMORI - REGIONE TOSCANA HEALTH 2013 PROT.11829-III/14 29/3/2013
- SIENABIOTECH/UNISI SMAG – REGIONE TOSCANA 2013 PROT.30106/-III/19
- EXONANODI APPLIED NANOTECHNOLOGIES – REGIONE TOSCANA PROT. N° 6081/2013 2013-2015
- SIENABIOTECH/UNISI CONTRATTO DI RICERCA PROGETTAZIONE E SINTESI DI PICCOLI PEPTIDI INTERFERENTI CON IL RICONOSCIMENTO LRP6 E DKK1 - 2013

PARTECIPAZIONE A COMITATI EDITORIALI

2013-2021 MEMBRO DELL' EDITORIAL ADVISORY BOARD DELLA RIVISTA JOURNAL OF MEDICINAL CHEMISTRY

COOPERAZIONE INTERNAZIONALE - CAPACITA' ORGANIZZATIVE - ESPERIENZA

ATTIVITA' DI COOPERAZIONE INTERNAZIONALE NEI PAESI DEL MEDITERRANEO ED IN AFRICA:

♦ **2015-2020: MEMBRO C.O.S. DEL PROGETTO DI COOPERAZIONE INTERNAZIONALE ITALIA/ BURKINA FASO "LUTTE CONTRE LE PALUDISME AU BURKINA FASO: FORMATION ET RECHERCHE EN PALUDOLOGIE" FINANZIATO DAL MAECI**

♦ **2013-2017: COLLABORA CON IL RETTORE ALL' ORGANIZZAZIONE DEL NETWORK MED-SOLUTIONS , L' HUB EUROPEO DI UNSDSN – UNITED NATIONS SUSTAINABLE DEVELOPMENT SOLUTIONS NETWORK, PER LA COOPERAZIONE SOSTENIBILE NEL BACINO DEL MEDITERRANEO, LA CUI SEDE E' PRESSO L' UNIVERSITA' DI SIENA**

♦ **2014-2017 COLLABORA CON IL RETTORE ALL' ORGANIZZAZIONE DEL PROGETTO P.R.I.M.A. -PARTNERSHIP IN RESEARCH AND INNOVATION IN THE MEDITERRANEAN AREA – ART.185 TRATTATO DELL' UNIONE - PROMOSSO DA TUTTI GLI STATI EUROPEI CHE SI AFFACCIANO NEL MEDITERRANEO E COORDINATO DALL' UNIVERSITA' DI SIENA PER MIUR CON SEDE A BARCELLONA SPAGNA**

♦ **2012-2015: PARTNER DEL PROGETTO E-PLUS/MAECI PER LA PROMOZIONE DEL SISTEMA UNIVERSITARIO PALESTINESE**

♦ **IL PROF. CAMPIANI DAL 2003 AL 2016 HA DIRETTO IL CENTRO EUROPEO NATSYNDRUGS TRA I CUI OBIETTIVI CI SONO LE ATTIVITA' DI COOPERAZIONE SOSTENIBILE INTERNAZIONALE IN AMBITO SANITARIO. AL NETWORK PARTECIPANO IT, TR, GR, UK E CH.**

♦ **NEL 2010 IL PROF CAMPIANI HA COFONDATO IL MALARIA NATIONAL RESEARCH CENTRE, CIRM A CUI PARTECIPANO 8 ATENEI ITALIANI.**

♦ **NEL PERIODO 2003-2008 E' STATO RAPPRESENTANTE ITALIANO NEL MANAGEMENT COMMITTEE DEL EU-COST ACTION B22 PER LE MALATTIE LEGATE ALLA POVERTA'**

♦ **DAL 2016 MEMBRO DEL EU-COST ACTION CM1406 EPYGENETICS**

PUBBLICAZIONI E H-INDEX

H-index = 47 (Scopus 2023) – 247 pubs (high IF Journals) – IF/pub = 5.22
Citazioni: 6881 (Scopus 2023) - inventore in vari brevetti nazionali ed internazionali

BREVETTI

G. Campiani et Al. Compounds with Atypical Antipsychotic Activity
RM2004A000178
US20080293689
WO 2005/097797

G. Campiani et Al. Apoptosis-inducing compounds
US6806267 (B1)
WO 1999056736
G. Campiani et Al. PYRROLO[2,1-B][1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY
WO 2000/00/06579
US 6,391,870
G. Campiani et Al. Pyrrolo[2,1-b][3,1] benzothiazepines and their use for the preparation of medicaments with antipsychotic activity
RM2000A000432
US20030186959
WO/2002/010175A1
G. Campiani et Al. NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS
WO2008101891(A1)
DE602008002563D1
US20100093726
G. Campiani et Al. ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
WO2006072608(A2)
G. Campiani et Al. Novel Aryl Piperazine Derivatives With Medical Utility
US20090238761
G. Campiani et Al. ARYL PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS
WO2008043839(A1)
US20100087445
G. Campiani et Al. CONDENSED PYRIMIDINONES ACTIVE ON GLUTAMATERGIC RECEPTORS
WO2008031888
G. Campiani et Al. CARBAMATE DERIVATIVES IN PARTICULAR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2010/105930 (A1)
G. Campiani et QUINOLIN-4-YLHYDRAZINE DERIVATIVES AS ANTIMALARIAL AGENT Al.
WO/2007/104695A1
G. Campiani et Al. ANTIMALARIAL AGENTS HAVING POLYAROMATIC STRUCTURE
WO/2007/104696A1

SCIENTIFIC PUBLICATIONS

2023-24

1. Synthetic derivatives of natural cinnamic acids as potential anti-colorectal cancer agents Falbo, F., Gemma, S., Koch, A., ...Campiani, G., Aiello, F. Chemical Biology and Drug Design, 2024, 103(1), e14415

2. Nutritionally enriched tomatoes (Solanum lycopersicum L.) grown with wood distillate: chemical and biological characterization for quality assessmentFedeli, R., Marotta, L., Frattaruolo, L., ...Campiani, G., Loppi, S. Journal of Food Science, 2023, 88(12), pp. 5324–5338

3. Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents Papa, A., Cursaro, I., Pozzetti, L., ...Campiani, G., Vincenzi, F. Archiv der Pharmazie, 2023, 356(12), 2300410

4. Development of 1-(2-aminophenyl)pyrrole-based amides acting as human topoisomerase I inhibitors Carullo, G., Mazzotta, S., Ceramella, J., Campiani, G.,...Aiello, F., Sinicropi, M.S. Archiv der Pharmazie, 2023, 356(10), 2300270

5. Development of Quinazolinone Derivatives as Modulators of Virulence Factors of Pseudomonas aeruginosa Cystic Fibrosis Strains Carullo, G., Di Bonaventura, G., Rossi, S., Campiani, G., ...Gemma, S., Pompilio, A. Molecules, 2023, 28(18), 6535

6. Expression, Purification, Structural and Functional Characterization of Recombinant Human Parvulin 17 Monti, A., Ronca, R., Campiani, G., Ruvo, M., Doti, N. Molecular Biotechnology, 2023, 65(3), pp. 337–349

7. Artificial intelligence-driven identification of morin analogues acting as CaV1.2 channel blockers: Synthesis and biological evaluation Carullo, G., Falbo, F.,Ahmed, A., Campiani, G., ...Saponara, S., Fusi, F. Bioorganic Chemistry, 2023, 131, 106326

8. Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions Papa, A., Pasquini, S., Galvani, F., Campiani, G.,...Lodola, A., Butini, S. European Journal of Medicinal Chemistry, 2023, 246, 114952

2022

1. Carullo, Gabriele ; Bottoni, Laura ; (...); Campiani, Giuseppe Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3 beta Inhibitors Promoting beta-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial Cells ChemMedChem 2022, DOI10.1002/cmdc.202200456
2. Saccoccia, Fulvio ; Pozzetti, Luca ; (...); Campiani, Giuseppe Crystal structures of Schistosoma mansoni histone deacetylase 8 reveal a novel binding site for allosteric inhibitors J.Biol.Chem. 2022, DOI10.1016/j.jbc.2022.102375
3. Marotta, Ludovica ; Rossi, Sara ; Campiani, Giuseppe ; (...); Gemma, Sandra The green chemistry of chalcones: Valuable sources of privileged core structures for drug discovery. Frontiers in Chemistry 2022, DOI10.3389/fchem.2022.988376
4. Fontana, Anna ; Cursaro, Ilaria ; (...); Campiani, Giuseppe A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors. Int. J. Mol. Sci. 2022, DOI10.3390/ijms231710014
5. Battista, Theo ; Federico, Stefano ; Campiani, Giuseppe ; (...); Gemma, Sandra Optimization of Potent and Specific Trypanothione Reductase Inhibitors: A Structure-Based Drug Discovery Approach ACS Infectious Diseases 2022, DOI10.1021/acsinfecdis.2c00325
6. Carullo, Gabriele ; Saponara, Simona ; Campiani, Giuseppe ; (...); Aiello, Francesca Novel Labdane Diterpenes-Based Synthetic Derivatives: Identification of a Bifunctional Vasodilator That Inhibits Ca(V)1.2 and Stimulates K(Ca)1.1 Channels Marine Drugs 2022, DOI10.3390/md20080515
7. Federico, Stefano ; Khan, Tuhina ; (...); Campiani, Giuseppe Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability Eur.J.Med. Chem. 2022, DOI10.1016/j.ejmech.2022.114409
8. Brogi, Simone ; Rossi, Sara ; Campiani, Giuseppe ; (...); Gemma, Sandra In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (M-pro). Computation 2022, DOI10.3390/computation10050069
9. Bergantini, Laura ; d'Alessandro, Miriana ; Campiani, Giuseppe ; (...); Bargagli, Elena Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis
10. Relitti, Nicola ; Saraswati, A. Prasanth ; Campiani, Giuseppe ; (...); Doti,

Nunzianna Design and Synthesis of Oligopeptidic Parvulin Inhibitors. CheMedChem 2022, DOI10.1002/cmdc.202200050
11. Monti, Alessandra ; Ronca, Raffaele ; Campiani, Giuseppe ; (...); Doti, Nunzianna Expression, Purification, Structural and Functional Characterization of Recombinant Human Parvulin 17. Mol. Biotech. 2022, DOI10.1007/s12033-022-00493-1
12. Brogi, Simone ; Ibba, Roberta ; (...); Campiani, Giuseppe Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases. Molecules 2022, DOI10.3390/molecules27082561
13. Campiani, Giuseppe ; Khan, Tuhina ; (...); Benedetti, Rosaria Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy. Eur. J. Med. Chem. 2022, DOI10.1016/j.ejmech.2022.114274
14. Pozzetti, Luca ; Ferrara, Francesca ; (...); Campiani, Giuseppe Extra Virgin Olive Oil Extracts of Indigenous Southern Tuscany Cultivar Act as Anti-Inflammatory and Vasorelaxant Nutraceuticals. Antioxidants 2022, DOI10.3390/antiox11030437
15. Papa, Alessandro ; Pasquini, Silvia ; Campiani, Giuseppe; (...); Vincenzi, Fabrizio Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. Cells 2022, DOI10.3390/cells11030471
16. Pozzetti, Luca ; Ibba, Roberta ; Campiani, Giuseppe; (...); Gemma, Sandra Total Synthesis of the Natural Chalcone Lophirone E, Synthetic Studies toward Benzofuran and Indole-Based Analogues, and Investigation of Anti-Leishmanial Activity. Molecules 2022, DOI10.3390/molecules27020463

2021

1. A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis Vanni, F., Lopresti, L., Zurli, V., Campiani, G., Butini, S., Ulivieri, C. Pharmacological Research, 2021, 174, 105965
2. A non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds Ghanim, M., Relitti, N., McManus, G., Campiani, G., Mok, K.H., Kelly, V.P. Scientific Reports, 2021, 11(1), 14069
3. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening Sirous, H., Campiani, G., Calderone, V., Brogi, S. Computers in Biology and Medicine, 2021, 137, 104808
4. Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors Campiani, G., Cavella, C., Osko, J.D., ...Gemma, S., Prasse, A. Journal of Medicinal Chemistry, 2021, 64(14), pp. 9960–9988
5. Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents Grillo, A., Fezza, F., Chemi, G., Campiani, G., Maccarrone, M., Di Giovanni, G. ACS Chemical Neuroscience, 2021, 12(9), pp. 1716–1736
6. Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity Relitti, N., Federico, S., Pozzetti, L., ...Gemma, S., Campiani, G. European Journal of Medicinal Chemistry, 2021, 215, 113227
7. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation Relitti, N., Saraswati, A.P., Chemi, G., ...Butini, S., Campiani, G. European Journal of Medicinal Chemistry, 2021, 212, 112998
8. Chapter 8: Natural Compounds and Synthetic Drugs to Target FAAH Enzyme Butini, S., Gemma, S., Campiani, G. RSC Drug Discovery Series, 2021, 2021-January(76), pp. 337–384

2020

1. (+)-(R)- and (−)-(S)-Perhexiline maleate: Enantioselective synthesis and functional studies on Schistosoma mansoni larval and adult stages. larval and adult stages Guidi, A., Prasanth Saraswati, A., Relitti, N., Campiani, G., Ruberti, G., Gemma, S. Bioorganic Chemistry **2020**, 102,104067
2. Selective Histone Deacetylase 6 Inhibitors Restore Cone Photoreceptor Vision or

Outer Segment Morphology in Zebrafish and Mouse Models of Retinal Blindness Sundaramurthi, H., Roche, S.L., Grice, G.L., Campiani, G., Nathan, J.A., Kennedy, B.N. Frontiers in Cell and Developmental Biology, **2020**, 8,689
3. Retinitis Pigmentosa and Retinal Degenerations: Deciphering Pathways and Targets for Drug Discovery and Development Carullo, G., Federico, S., Relitti, N., Gemma, S., Butini, S., Campiani, G. ACS Chemical Neuroscience, **2020**, 11(15), 2173-2191
4. Ionotropic Glutamate Receptor GluA2 in Complex with Bicyclic Pyrimidinedione-Based Compounds: When Small Compound Modifications Have Distinct Effects on Binding Interactions Frydenvang, K., Pickering, D.S., Kshirsagar, G.U., Campiani G., Butini, S., Kastrup, J.S. ACS Chemical Neuroscience, **2020**, 11, 1791-1800
5. Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas. Khan, T., Relitti, N., Brindisi, M., Butini, S., Campiani, G. Medicinal Research Reviews, **2020**, 40(3), pp. 1002-1060
6. Computer-driven development of an in silico tool for finding selective histone deacetylase 1 inhibitors. Sirous, H., Campiani, G., Brogi, S., Calderone, V., Chemi, G. Molecules, **2020**, 25(8),1952
7. Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents. Saccoccia, F., Brindisi, M., Gimmelli, R., Campiani, G., Gemma, S., Ruberti, G. ACS Infectious Diseases, **2020**, 6(1), 100-113
8. Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases Brindisi, M., Saraswati, A.P., Brogi, S., Gemma, S., Butini, S., Campiani, G. J. Med. Chem., **2020**, 63(1), 23-39
9. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists Federico, S., Pozzetti, L., Papa, A., Carullo, G., Gemma, S., Butini, S., Campiani, G., Relitti, N. J. Med. Chem., **2020**, 63, 13466-13513.
10. Cinnamides Target Leishmania amazonensis Arginase Selectively da Silva, E.R., Come, J.A.A.D.S.S., Brogi, S., Calderone, V., Chemi, G., Campiani, G., Oliveira, T.M.F.S., Pham, T.-N., Pudlo, M., Girard, C., Maquiaveli, C.D.C. Molecules, **2020**, 25(22)
11. Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation Saraswati, A.P., Relitti, N., Brindisi, M., ...Christianson, D.W., Campiani, G. ACS Medicinal Chemistry Letters, **2020**, 11, 2268–2276
12. Telomerase-based cancer therapeutics: A review on their clinical trials Relitti, N., Saraswati, A.P., Federico, S., ...Butini, S., Campiani, G. Current Topics in Medicinal Chemistry, **2020**, 20, 433–457

2019

1. Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach, Sirous, H.; Chemi, G.; Gemma, S.; Butini, S.; Debyser, Z.; Christ, F.; Saghaie, L.; Brogi, S.; Fassihi, A.; Campiani, G.; Brindisi, M.,. *Front Chem* **2019,** *7, 574*.
2. Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II). D'Alessandro, S.; Alfano, G.; Di Cerbo, L.; Brogi, S.; Chemi, G.; Relitti, N.; Brindisi, M.; Lamponi, S.; Novellino, E.; Campiani, G.; Gemma, S.; Basilico, N.; Taramelli, D.; Baratto, M. C.; Pogni, R.; Butini, S., *Bioorganic chemistry* **2019,** *89, 103020*.
3. Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors. Saraswati, A. P.; Relitti, N.; Brindisi, M.; Gemma, S.; Zisterer, D.; Butini, S.; Campiani, G., *Drug discovery today* **2019,** *24* (7), 1370-1388.
4. Dietary polyphenols rutin, taxifolin and quercetin related compounds target Leishmania amazonensis arginase. da Silva, E. R.; Brogi, S.; Lucon, J. F.; Campiani, G.; Gemma, S.; Maquiaveli, C. D., *Food Funct* **2019,** *10* (6), 3172-3180.
5. A light in the dark: state of the art and perspectives in optogenetics and

optopharmacology for restoring vision. Chemi, G.; Brindisi, M.; Brogi, S.; Relitti, N.; Butini, S.; Gemma, S.; Campiani, G., *Future medicinal chemistry* **2019,** *11* (5), 463-487.
6. Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders. Brogi, S.; Campiani, G.; Brindisi, M.; Butini, S., *ACS Medicinal Chemistry Letters* **2019,** *10* (3), 228-236.
7. Cinnamic acids derived compounds with antileishmanial activity target Leishmania amazonensis arginase.da Silva, E. R.; Brogi, S.; Grillo, A.; Campiani, G.; Gemma, S.; Vieira, P. C.; Maquiaveli, C. D., *Chemical biology & drug design* **2019,** *93* (2), 139-146.
8. Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. Brindisi, M.; Ulivieri, C.; Alfano, G.; Gemma, S.; Balaguer, F. D.; Khan, T.; Grillo, A.; Chemi, G.; Menchon, G.; Prota, A. E.; Olieric, N.; Lucena-Agell, D.; Barasoain, I.; Diaz, J. F.; Nebbioso, A.; Conte, M.; Lopresti, L.; Magnano, S.; Amet, R.; Kinsella, P.; Zisterer, D. M.; Ibrahim, O.; O'Sullivan, J.; Morbidelli, L.; Spaccapelo, R.; Baldari, C.; Butini, S.; Novellino, E.; Campiani, G.; Altucci, L.; Steinmetz, M. O.; Brogi, S., *Eur J Med Chem* **2019,** *162*, 290-320.
9. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction. Sirous, H.; Chemi, G.; Campiani, G.; Brogi, S., *Computational biology and chemistry* **2019**, 83, 107105.
10. Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems.Grillo, A.; Chemi, G.; Brogi, S.; Brindisi, M.; Relitti, N.; Fezza, F.; Fazio, D.; Castelletti, L.; Perdona, E.; Wong, A.; Lamponi, S.; Pecorelli, A.; Benedusi, M.; Fantacci, M.; Valoti, M.; Valacchi, G.; Micheli, F.; Novellino, E.; Campiani, G.; Butini, S.; Maccarrone, M.; Gemma, S., *Eur J Med Chem* **2019**, 183, 111674.
11. Dealing with schistosomiasis: Current drug discovery strategies. Gemma, S., Federico, S., Brogi, S., Brindisi, M., Butini, S., Campiani, G**.** *Annual Reports in Medicinal Chemistry,* **2019,** 55, 107-138 Chapter in Book, DOI:10.1016/bs.armc.2019.06.002
12. A repurposing approach for uncovering the anti-tubercular activity of FDA-approved drugs with Potential Multi-Targeting Profiles Battah, B., Chemi, G., Butini, S., Campiani, G., (...), Delogu, G., Gemma, S. Molecules 2019, 24(23),4373
13. Synthesis, molecular modelling and biological studies of 3-hydroxy-pyrane-4-one and 3-hydroxy-pyridine-4-one derivatives as HIV-1 integrase inhibitors Sirous, H., Fassihi, A., Brogi, S., Campiani, G., Saghaie, L., Memarian, H.R. Medicinal Chemistry **2019** 15(7), pp. 755-770

2018

1. (S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: further exploration of bioisosteric replacements and structural and biological investigation. Brogi S, Brindisi M, Butini S, Kshirsagar G U., Maramai S, Chemi G, Gemma S, Campiani G, Novellino E, Fiorenzani P, Pinassi J, Aloisi A M, Gynther M, Venskutonytė R, Han L, Frydenvang K, Kastrup Jette S, Pickering D S. J.Med. Chem, **2018**, 61, p. 2124-2130
2. Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]- N -[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues. Vallone A, D'Alessandro S, Brogi S, Brindisi M, Chemi, G, Alfano G, Lamponi S, Lee SG, Jez J M., Koolen K. J. M., Dechering K. J., Saponara S, Fusi F, Gorelli B, Taramelli D, Parapini S, Caldelari R, Campiani G, Gemma S, Butini S. Eur.J.Med Chem, **2018**, 150, p. 698-718.
3. Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. Paolino M, Brindisi M, Vallone A, Butini S, Campiani G, Nannicini C, Giuliani G, Anzini M, Lamponi S, Giorgi G, Sbardella D, Ferraris D M, Marini S, Coletta, M, Paolucci I, Minerva M, Delogu G, Pepponi I, Goletti D, Cappelli A, Gemma

S, Brogi S. ChemMedChem, **2018**, 13, p. 422-430.
4. iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated α-tubulin defect which improves after iHDAC6 treatment in Rett syndrome Landucci, E., Brindisi, M., Bianciardi, L., Campiani, G., Meloni, I. et Al Experimental Cell Research **2018**, 368(2), pp. 225-235
5. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies Brindisi, M., Senger, J., Cavella, C., Campian, G., Altucci, L., Brogi, S. et Al European Journal of Medicinal Chemistry **2018**, 157, pp. 127-138
6. Development of a Multiplexed Activity-Based Protein Profiling Assay to Evaluate Activity of Endocannabinoid Hydrolase Inhibitors. Janssen APA, van der Vliet D, Bakker AT, Jiang M, Grimm SH, Campiani G, Butini S, van der Stelt M. ACS Chem Biol. 2018 Sep 21;13(9):2406-2413
7. Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. Brindisi M, Borrelli G, Brogi S, Grillo A, Maramai S, Paolino M, Benedusi M, Pecorelli A, Valacchi G, Di Cesare Mannelli L, Ghelardini C, Allarà M, Ligresti A, Minetti P, Campiani G, di Marzo V, Butini S, Gemma S. ChemMedChem. **2018** Oct 8;13(19):2090-2103.
8. Synthetic studies toward bicyclic endoperoxides presenting polar side chains. Gemma, S.; di Cerbo, L.; Relitti, N.; Vallone, A.; Brindisi, M.; Brogi, S.; Chemi, G.; Novellino, E.; Campiani, G.; Butini, S., Tetrahedron Lett **2018**, 59 (49), 4330-4333.
9. Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents. Federico, S.; Khan, T.; Relitti, N.; Chemi, G.; Brindisi, M.; Brogi, S.; Novellino, E.; Zisterer, D. M.; Campiani, G.; Gemma, S.; Butini, S., A Tetrahedron Lett **2018**, 59 (51), 4466-4470.
10. Discovery of iminobenzimidazole derivatives as novel cytotoxic agents, Chouha, N., Hammoud, H., Brogi, S., Campiani, G., Welsch, C., Robert, C., Vagner, S., Cresteil, T., Bentouhami, E., Désaubry, L., Open Medicinal Chemistry Journal, **2018**, 12 (1), 74-83.

SCIENTIFIC PUBLICATIONS 2008-2017

1. The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity. Colangeli R, Pierucci M, Benigno A, Campiani G, Butini S, Di Giovanni G. Sci. Rep. 2017 Sep 11;7(1):11152. doi: 10.1038/s41598-017-11606-
2. First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents. Brogi S, Ramunno A, Savi L, Chemi G, Alfano G, Pecorelli A, Pambianchi E, Galatello P, Compagnoni G, Focher F, Biamonti G, Valacchi G, Butini S, Gemma S, Campiani G, Brindisi M. Eur J Med Chem. 2017 Sep 29;138:438-457.
3. Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity. Chemi G, Gemma S, Campiani G, Brogi S, Butini S, Brindisi M. Front Chem. 2017 Feb 23;5:7. doi: 10.3389/fchem.2017.00007.
4. Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX. Brogi S, Fiorillo A, Chemi G, Butini S, Lalle M, Ilari A, Gemma S, Campiani G. Eur J Med Chem. 2017 Jul 28;135:479-49
5. Identification of novel fluorescent probes preventing PrPSc replication in prion diseases. Zaccagnini L, Brogi S, Brindisi M, Gemma S, Chemi G, Legname G, Campiani G, Butini S. Eur J Med Chem. 2017 Feb 15;127:859-873.
6. Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation. Brogi S, Maramai S, Brindisi M, Butini S, Campiani G, Gemma S. ChemMedChem 2017, 12, 2074-2085
7. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J. Prog Neurobiol. 2017, 151, 4-34.
8- Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. Brindisi M, Maramai S, Grillo A, Brogi S, Butini S, Novellino E, Allara' M, Ligresti A, Campiani G, Di Marzo V, Gemma S. RCS Advances 2016, 6(69), 64651-64664DOI: 10.1039/c6ra12524g.

9. Donepezil like multifunctional agents: design, synthesis, molecular modeling and biological evaluation, Campiani G et Al Eur. J. Med. Chem. 2016, 121, 864-879
10. Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. Brindisi M, Maramai S, Gemma S, Brogi S, Grillo A, Di Cesare Mannelli L, Gabellieri E, Lamponi S, Saponara S, Gorelli B, Tedesco D, Bonfiglio T, Landry C, Jung KM, Armirotti A, Luongo L, Ligresti A, Piscitelli F, Bertucci C, Dehouck MP, Campiani G, Maione S, Ghelardini C, Pittaluga A, Piomelli D, Di Marzo V, Butini S. J Med Chem. 2016 Mar 24;59(6):2612-32.
11. Fiore, D.; Proto, M. C.; Pisanti, S.; Picardi, P.; Pagano Zottola, A. C.; Butini, S.; Gemma, S.; Casagni, A.; Laezza, C.; Vitale, M.; Ligresti, A.; Di Marzo, V.; Zisterer, D. M.; Nathwani, S.; Williams, D. C.; Campiani, G.; Gazzerro, P.; Bifulco, M. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. Cancer. Biol. Ther. 2016, 17, 849-858
12. Endocannabinoid modulation of predator stress-induced long-term anxiety in rats. Lim J, Igarashi M, Jung KM, Butini S, Campiani G, Piomelli D. Neuropsychopharmacology 2016, 41, 1329-1339.
13. The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15. Kinsella P, Greene LM, Bright SA, Pollock JK, Butini S, Campiani G, Bauer S, Williams DC, Zisterer DM. Invest New Drugs. 2016 34(2):159-67.
14. In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors. Brogi S, Giovani S, Brindisi M, Gemma S, Novellino E, Campiani G, Blackman MJ, Butini S. J Mol Graph Model. 2016 Mar;64:121-30.
15. Verbascoside Inhibits Promastigote Growth and Arginase Activity of Leishmania amazonensis. Maquiaveli CC, Lucon-Júnior JF, Brogi S, Campiani G, Gemma S, Vieira PC, Silva ER. J Nat Prod. 2016 27, 1459-1463.
16. Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases Maramai S, Gemma S, Brogi S,Campiani G, Butini S, Stark H, Brindisi M. Front Neurosci. 2016;10:451.
17. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. Brindisi M, Cavella C, Brogi S, Nebbioso A, Senger J, Maramai S, Ciotta A, Iside C, Butini S, Lamponi S, Novellino E, Altucci L, Jung M, Campiani G, Gemma S. Future Med Chem. 2016 8(13):1573-87.
18. Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells.Lennon JC, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM.Invest New Drugs. 2016 Oct;34(5):663-7
19. Polypharmacology of dopamine receptor ligands. Butini S, Nikolic K, Kassel S, Brückmann H, Filipic S, Agbaba D, Gemma S, Brogi S, Brindisi M, Campiani G, Stark H. Prog Neurobiol. 2016 Jul;142:68-103
20. Development of of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTUV) fragment of pretubulysin and analogs. Brindisi M, Maramai S, Grillo A, Brogi S, Butini S, Novellino E, Campiani G, Gemma S Tetrahedron Lett. 2016, 57, 920-923.
21. Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors. Brindisi M, Brogi S, Giovani S, Gemma S, Lamponi S, De Luca F, Novellino E, Campiani G, Docquier JD, Butini S. J Enzyme Inhib Med Chem. 2016 Apr 28:1-12.
22. Development of novel cyclic peptides as pro-apoptotic agents. Brindisi M, Maramai S, Brogi S, Fanigliulo E, Butini S, Guarino E, Casagni A, Lamponi S, Bonechi C, Nathwani SM, Finetti F, Ragonese F, Arcidiacono P, Campiglia P, Valenti S, Novellino E, Spaccapelo R, Morbidelli L, Zisterer DM, Williams CD, Donati A, Baldari C, Campiani G, Ulivieri C, Gemma S. Eur J Med Chem. 2016 117:301-320.
23. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. Nathwani SM, Greene LM, Butini S, Campiani G, Williams DC, Samali A, Szegezdi E, Zisterer DM. Int J Oncol. 2016 49, 74-88.

24. Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines. Greene LM, Butini S, Campiani G, Williams DC, Zisterer DM.J Cancer. 2016 ,7(15):2367-2377
25. Savi, L.; Brindisi, M.; Alfano, G.; Butini, S.; La Pietra, V.; Novellino, E.; Marinelli, L.; Lossani, A.; Focher, F.; Cavella, C.; Campiani, G.; Gemma, S. Site-directed Mutagenesis of Key Residues Unveiled a Novel Allosteric Site on Human Adenosine Kinase for Pyrrolobenzoxa(thia)zepinone Non-Nucleoside Inhibitors. Chem. Biol. Drug. Des. 2016, 87, 112-12023.
26. Brindisi, M.; Brogi, S.; Relitti, N.; Vallone, A.; Butini, S.; Gemma, S.; Novellino, E.; Colotti, G.; Angiulli, G.; Di Chiaro, F.; Fiorillo, A.; Ilari, A.; Campiani, G. Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking. Sci. Rep. 2015, 5, 9705.
27. Brindisi, M.; Gemma, S.; Kunjir, S.; Di Cerbo, L.; Brogi, S.; Parapini, S.; D'Alessandro, S.; Taramelli, D.; Habluetzel, A.; Tapanelli, S.; Lamponi, S.; Novellino, E.; Campiani, G.; Butini, S. Synthetic spirocyclic endoperoxides: new antimalarial scaffolds. Medchemcomm 2015, 6, 357-362.
28. Giovani, S.; Penzo, M.; Butini, S.; Brindisi, M.; Gemma, S.; Novellino, E.; Campiani, G.; Blackman, M. J.; Brogi, S. Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors. RSC Adv. 2015, 5, 22431-22448.
29. O'Callaghan, K.; Palagano, E.; Butini, S.; Campiani, G.; Williams, D. C.; Zisterer, D. M.; O'Sullivan, J. Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines. Mol Med Rep 2015, 12, 3748-3754.
30. Spallarossa, A.; Caneva, C.; Caviglia, M.; Alfei, S.; Butini, S.; Campiani, G.; Gemma, S.; Brindisi, M.; Zisterer, D. M.; Bright, S. A.; Williams, C. D.; Crespan, E.; Maga, G.; Sanna, G.; Delogu, I.; Collu, G.; Loddo, R. Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents. Eur. J. Med. Chem. 2015, 102, 648-660.
31. Brogi, S.; Brindisi, M.; Joshi, B. P.; Sanna Coccone, S.; Parapini, P.; Basilico, B.; Novellino, E.; Campiani, G.; Gemma, S.; Butini, S. Exploring clotrimazole-based pharmacophore: 3D-QSAR studies and synthesis of novel antiplasmodial agents. Bioorg. Med. Chem. Lett. 2015-, 25, 5412-5418 doi:10.1016/j.bmcl.2015.1009.1007.
32. Brindisi, M.; Butini, S.; Franceschini, S.; Brogi, S.; Trotta, F.; Ros, S.; Cagnotto, A.; Salmona, M.; Casagni, A.; Andreassi, M.; Saponara, S.; Gorelli, B.; Weikop, P.; Mikkelsen, J. D.; Scheel-Kruger, J.; Sandager-Nielsen, K.; Novellino, E.; Campiani, G.; Gemma, S. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: Synthesis, biological characterization, and behavioral studies. Journal of Medicinal Chemistry 2014, 57, 9578-9597.
33. Giovani, S.; Penzo, M.; Brogi, S.; Brindisi, M.; Gemma, S.; Novellino, E.; Savini, L.; Blackman, M. J.; Campiani, G.; Butini, S. Rational design of the first difluorostatone-based PfSUB1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2014, 24, 3582-3586.
34. Gemma, S.; Brogi, S.; Patil, P. R.; Giovani, S.; Lamponi, S.; Cappelli, A.; Novellino, E.; Brown, A.; Higgins, M. K.; Mustafa, K.; Szestak, T.; Craig, A. G.; Campiani, G.; Butini, S.; Brindisi, M. From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum. RSC Advances 2014, 4, 4769-4781.
35. Gemma, S.; Brogi, S.; Novellino, E.; Campiani, G.; Maga, G.; Brindisi, M.; Butini, S. HCV-targeted antivirals: Current status and future challenges. Current Pharmaceutical Design 2014, 20, 3445-3464.
36. Brogi, S.; Butini, S.; Maramai, S.; Colombo, R.; Verga, L.; Lanni, C.; De Lorenzi, E.; Lamponi, S.; Andreassi, M.; Bartolini, M.; Andrisano, V.; Novellino, E.; Campiani, G.; Brindisi, M.; Gemma, S. Disease-modifying anti-Alzheimer's drugs: Inhibitors of human cholinesterases interfering with β-amyloid aggregation. CNS Neuroscience and Therapeutics 2014, 20, 624-632.
37. Gori M, Campiani G, Rossi A, Setacci C. The web of clinical data. J Cardiovasc Surg (Torino). 2014 Oct;55(5):717-8.
38. Castriconi F, Paolino M, Giuliani G, Anzini M, Campiani G, Mennuni L, Sabatini C,

Lanza M, Caselli G, De Rienzo F, Menziani MC, Sbraccia M, Molinari P, Costa T, Cappelli A. Synthesis and structure-activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold. Eur J Med Chem. 2014 Jul 23;82:36-46.
39. Lennon JC, Bright SA, Carroll E, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM. The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells.Biochem Pharmacol. 2014 Feb 15;87(4):611-24.39. Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds. Cappelli A, Manini M, Valenti S, Castriconi F, Giuliani G, Anzini M, Brogi S, Butini S, Gemma S, Campiani G, Giorgi G, Mennuni L, Lanza M, Giordani A, Caselli G, Letari O, Makovec F. Eur J Med Chem. 2013, 63C, 85-94.
40. Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties. Butini S, Gemma S, Brindisi M, Maramai S, Minetti P, Celona D, Napolitano R, Borsini F, Cabri W, Fezza F, Merlini L, Dallavalle S, Campiani G, Maccarrone M. Bioorg Med Chem Lett. 2013, 23, 492-5.
41. Novel peptidomimetics as BACE-1 inhibitors: synthesis, molecular modeling, and biological studies. Butini S, Gabellieri E, Brindisi M, Casagni A, Guarino E, Huleatt PB, Relitti N, La Pietra V, Marinelli L, Giustiniano M, Novellino E, Campiani G, Gemma S. Bioorg Med Chem Lett. 2013, 23, 85-9.
42. Multifunctional cholinesterase and amyloid beta fibrillization modulators. Synthesis and biological investigation Butini, S. Brindisi, M. Brogi, S. Maramai, S. Guarino, E. Panico, A. Saxena, A. Chauhan, V. Colombo, R. Verga, L. De Lorenzi, E. Bartolini, M. Andrisano, V. Novellino, E. Campiani, G. Gemma, S. ACS Medicinal Chemistry Letters, 2013, 4, 1178-1182
43. A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues their analogues Brindisi, M. Gemma, S. Alfano, G. Kshirsagar, G. Novellino, E. Campiani, G. Butini, S. Tetrahedron Letters, 2013, 54, 5387-5390
44. Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells Greene, L.M. Nolan, D.P. Regan-Komito, D. Campiani, G. Williams, D.C. Zisterer, D.M. Int. J. Oncology, 2013, 43, 927-935
45. A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides Gemma, S. Kunjir, S. Brindisi, M. Novellino, E. Campiani, G. Butini, S. Tetrahedron Letters, 2013, 54, 1233-1235
46. The structural evolution of β-secretase inhibitors: A focus on the development of small-molecule inhibitors Butini, S. Brogi, S. Novellino, E. Campiani, G. Ghosh, A.K. Brindisi, M. Gemma, S. Current Topics in Medicinal Chemistry, 2013, 13, 1787-1807
47. The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells Lysaght, J. Verma, N.K. Maginn, E.N. Ryan, J.M. Campiani, G. Zisterer, D.M. Williams, D.C. Browne, P.V. Lawler, M.P. McElligott, A.M. International Journal of Oncology 2013, 42, 239-246
48. A stereoselective approach to peptidomimetic BACE1 inhibitors Butini, S. Gabellieri, E. Brindisi, M. Giovani, S. Maramai, S. Kshirsagar, G. Guarino, E. Brogi, S. La Pietra, V. Giustiniano, M. Marinelli, L. Novellino, E. Campiani, G. Cappelli, A. Gemma, S. Eur J Med Chem 2013, 70, 233-247
49. Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents. Gemma S, Camodeca C, Brindisi M, Brogi S, Kukreja G, Kunjir S, Gabellieri E, Lucantoni L, Habluetzel A, Taramelli D, Basilico N, Gualdani R, Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Martin RE, Summers RL, Lamponi S, Savini L, Fiorini I, Valoti M, Novellino E, Campiani G, Butini S. J Med Chem. 2012, 55, 10387-404.
50. A straightforward approach for engineering efficacy and selectivity at GPCRs. Butini S, Gemma S, Campiani G. J Med Chem. 2012, 55(15):6687-8.
51. Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1. Gemma S, Giovani S, Brindisi M, Tripaldi P, Brogi S, Savini L, Fiorini I, Novellino E, Butini S, Campiani G, Penzo M, Blackman MJ. Bioorg Med Chem Lett. 2012, 22(16):5317-21.
52.Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further

structure-activity relationships, in vivo studies, and preliminary toxicity profiling. Gemma S, Camodeca C, Sanna Coccone S, Joshi BP, Bernetti M, Moretti V, Brogi S, Bonache de Marcos MC, Savini L, Taramelli D, Basilico N, Parapini S, Rottmann M, Brun R, Lamponi S, Caccia S, Guiso G, Summers RL, Martin RE, Saponara S, Gorelli B, Novellino E, Campiani G, Butini S. J Med Chem. 2012, 55(15):6948-67.
53.Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases. Butini S, Brindisi M, Gemma S, Minetti P, Cabri W, Gallo G, Vincenti S, Talamonti E, Borsini F, Caprioli A, Stasi MA, Di Serio S, Ros S, Borrelli G, Maramai S, Fezza F, Campiani G, Maccarrone M. J Med Chem. 2012, 55(15):6898-915.
54. Bartolommei, G.; Tadini-Buoninsegni, F.; Moncelli, M. R.; Gemma, S.; Camodeca, C.; Butini, S.; Campiani, G.; Lewis, D.; Inesi, G., The Ca(2+)-ATPase (SERCA1) Is Inhibited by 4-Aminoquinoline Derivatives through Interference with Catalytic Activation by Ca(2+), Whereas the ATPase E(2) State Remains Functional. J. Biol. Chem. 2011, 286, 38383-38389.
55. Gemma, S.; Kunjir, S.; Coccone, S. S.; Brindisi, M.; Moretti, V.; Brogi, S.; Novellino, E.; Basilico, N.; Parapini, S.; Taramelli, D.; Campiani, G.; Butini, S., Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues. J. Med. Chem. 2011, 54, 5949-5953.
56. Bane, F. T.; Bannon, J. H.; Pennington, S. R.; Campiani, G.; Williams, D. C.; Zisterer, D. M.; Mc Gee, M. M., The Microtubule- Targeting Agents, PBOX-6 [Pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and Paclitaxel, Induce Nucleocytoplasmic Redistribution of the Peptidyl-Prolyl Isomerases, Cyclophilin A and Pin1, in Malignant Hematopoietic Cells. J. Pharmacol. Exp. Ther. 2011, 338, 729-729.
57. Venskutonyte, R.; Butini, S.; Coccone, S. S.; Gemma, S.; Brindisi, M.; Kumar, V.; Guarino, E.; Maramai, S.; Valenti, S.; Amir, A.; Valades, E. A.; Frydenvang, K.; Kastrup, J. S.; Novellino, E.; Campiani, G.; Pickering, D. S., Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization. J. Med. Chem. 2011, 54, 4793-4805.
58. Butini, S.; Gemma, S.; Brindisi, M.; Borrelli, G.; Fiorini, I.; Samuele, A.; Karytinos, A.; Facchini, M.; Lossani, A.; Zanoli, S.; Campiani, G.; Novellino, E.; Focher, F.; Maga, G., Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants. Bioorg. Med. Chem. Lett. 2011, 21, 3935-3938.
59. Gemma, S.; Butini, S.; Campiani, G.; Brindisi, M.; Zanoli, S.; Romano, M. P.; Tripaldi, P.; Savini, L.; Fiorini, I.; Borrelli, G.; Novellino, E.; Maga, G., Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase. Bioorg. Med. Chem. Lett. 2011, 21, 2776-2779.
60. Patil, P. R.; Gemma, S.; Campiani, G.; Craig, A. G., Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate. Malaria J. 2011, 10, 348.
61. Butini, S.; Gemma, S.; Brindisi, M.; Borrelli, G.; Lossani, A.; Ponte, A. M.; Torti, A.; Maga, G.; Marinelli, L.; La Pietra, V.; Fiorini, I.; Lamponi, S.; Campiani, G.; Zisterer, D. M.; Nathwani, S. M.; Sartini, S.; La Motta, C.; Da Settimo, F.; Novellino, E.; Focher, F., Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies. J. Med. Chem. 2011, 54, 1401-1420.
62. Forde, J. C.; Maginn, E. N.; McNamara, G.; Martin, L. M.; Campiani, G.; Williams, D. C.; Zisterer, D.; McElligott, A. M.; Lawler, M.; Lynch, T. H.; Hollywood, D.; Marignol, L., Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro. Cancer Biol. Ther. 2011, 11, 421-428.
63. Maginn, E. N.; Browne, P. V.; Hayden, P.; Vandenberghe, E.; MacDonagh, B.; Evans, P.; Goodyer, M.; Tewari, P.; Campiani, G.; Butini, S.; Williams, D. C.; Zisterer, D. M.; Lawler, M. P.; McElligott, A. M., PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. Brit. J. Cancer 2011, 104, 281-289.
64. Gemma, S.; Colombo, L.; Forloni, G.; Savini, L.; Fracasso, C.; Caccia, S.; Salmona, M.; Brindisi, M.; Joshi, B. P.; Tripaldi, P.; Giorgi, G.; Taglialatela-Scafati, O.; Novellino, E.; Fiorini, I.; Campiani, G.; Butini, S., Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils. Org. Biomol. Chem. 2011, 9, 5137-5148.

65. Nathwani, S. M.; Cloonan, S. M.; Stronach, M.; Campiani, G.; Lawler, M.; Williams, D. C.; Zisterer, D. M., Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells. Oncol. Rep. 2010, 24, 1499-1507.
66. Nathwani, S. M.; Butler, S.; Fayne, D.; McGovern, N. N.; Sarkadi, B.; Meegan, M. J.; Lloyd, D. G.; Campiani, G.; Lawler, M.; Williams, D. C.; Zisterer, D. M., Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemoth. Pharm. 2010, 66, 585-596.
67. Bright, S. A.; Campiani, G.; Deininger, M. W.; Lawler, M.; Williams, D. C.; Zisterer, D. M., Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. Biochem. Pharmacol. 2010, 80, 31-38.
68. Butini, S.; Campiani, G.; Franceschini, S.; Trotta, F.; Kumar, V.; Guarino, E.; Borrelli, G.; Fiorini, I.; Novellino, E.; Fattorusso, C.; Persico, M.; Orteca, N.; Sandager-Nielsen, K.; Jacobsen, T. A.; Madsen, K.; Scheel-Kruger, J.; Gemma, S., Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D(3) and Serotonin 5-HT(1A) and 5-HT(2A) Receptors. J. Med. Chem. 2010, 53, 4803-4807.
69. Bright, S. A.; McElligott, A. M.; O'Connell, J. W.; O'Connor, L.; Carroll, P.; Campiani, G.; Deininger, M. W.; Conneally, E.; Lawler, M.; Williams, D. C.; Zisterer, D. M., Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Brit. J. Cancer 2010, 102, 1474-1482.
70. Gemma, S.; Gabellieri, E.; Coccone, S. S.; Marti, F.; Taglialatela-Scafati, O.; Novellino, E.; Campiani, G.; Butini, S., Synthesis of Dihydroplakortin, 6-epi-Dihydroplakortin, and Their C10-Desethyl Analogues. J. Org. Chem. 2010, 75, 2333-2340.
71. Cappelli, A.; Butini, S.; Brizzi, A.; Gemma, S.; Valenti, S.; Giuliani, G.; Anzini, M.; Mennuni, L.; Campiani, G.; Brizzi, V.; Vomero, S., The Interactions of the 5-HT(3) Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium. Curr. Top. Med. Chem. 2010, 10, 504-526.
72. Nathwani, S. M.; Butler, S.; Meegan, M. J.; Campiani, G.; Lawler, M.; Williams, D. C.; Zisterer, D. M., Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines. Cancer Chemoth. Pharm. 2010, 65, 289-300.
73. Malaria chemotherapy: Recent advances in drug development Gemma, S. Travagli, V. Savini, L. Novellino, E. Campiani, G. Butini, S. Recent Patents on Anti-Infective Drug Discovery 2010, 5, 195-225
74. Butini, S.; Budriesi, R.; Hamon, M.; Morelli, E.; Gemma, S.; Brindisi, M.; Borrelli, G.; Novellino, E.; Fiorini, I.; Ioan, P.; Chiarini, A.; Cagnotto, A.; Mennini, T.; Fracasso, C.; Caccia, S.; Campiani, G., Novel, Potent, and Selective Quinoxaline-Based 5-HT(3) Receptor Ligands. 1. Further Structure-Activity Relationships and Pharmacological Characterization. J. Med. Chem. 2009, 52, 6946-6950.
75. McElligott, A. M.; Maginn, E. N.; Greene, L. M.; McGuckin, S.; Hayat, A.; Browne, P. V.; Butini, S.; Campiani, G.; Catherwood, M. A.; Vandenberghe, E.; Williams, D. C.; Zisterer, D. M.; Lawler, M., The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia. Cancer Res. 2009, 69, 8366-8375.
76. Gemma, S.; Marti, F.; Gabellieri, E.; Campiani, G.; Novellino, E.; Butini, S., Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials. Tetrahedron Lett. 2009, 50, 5719-5722.
77. Ferlini, C.; Cicchillitti, L.; Raspaglio, G.; Bartollino, S.; Cimitan, S.; Bertucci, C.; Mozzetti, S.; Gallo, D.; Persico, M.; Fattorusso, C.; Campiani, G.; Scambia, G., Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77. Cancer Res. 2009, 69, 6906-6914.
78. Gemma, S.; Savini, L.; Altarelli, M.; Tripaldi, P.; Chiasserini, L.; Coccone, S. S.; Kumar, V.; Camodeca, C.; Campiani, G.; Novellino, E.; Clarizio, S.; Delogu, G.; Butini, S., Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies. Bioorg. Med. Chem. 2009, 17,

6063-6072.
79. Morelli, E.; Gemma, S.; Budriesi, R.; Campiani, G.; Novellino, E.; Fattorusso, C.; Catalanotti, B.; Coccone, S. S.; Ros, S.; Borrelli, G.; Kumar, V.; Persico, M.; Fiorini, I.; Nacci, V.; Ioan, P.; Chiarini, A.; Hamon, M.; Cagnotto, A.; Mennini, T.; Fracasso, C.; Colovic, M.; Caccia, S.; Butini, S., Specific Targeting of Peripheral Serotonin 5-HT(3) Receptors. Synthesis, Biological Investigation, and Structure-Activity Relationships. J. Med. Chem. 2009, 52, 3548-3562.
80. Butini, S.; Brindisi, M.; Cosconati, S.; Marinelli, L.; Borrelli, G.; Coccone, S. S.; Ramunno, A.; Campiani, G.; Novellino, E.; Zanoli, S.; Samuele, A.; Giorgi, G.; Bergamini, A.; Di Mattia, M.; Lalli, S.; Galletti, B.; Gemma, S.; Maga, G., Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations. J. Med. Chem. 2009, 52, 1224-1228.
81. Bright, S. A.; Greene, L. M.; Greene, T. F.; Campiani, G.; Butini, S.; Brindisi, M.; Lawler, M.; Meegan, M. J.; Williams, D. C.; Zisterer, D. M., The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. Biochem. Pharmacol. 2009, 77, 310-321.
82. Gemma, S.; Campiani, G.; Butini, S.; Joshi, B. P.; Kukreja, G.; Coccone, S. S.; Bernetti, M.; Persico, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Taramelli, D.; Basilico, N.; Parapini, S.; Yardley, V.; Croft, S.; Keller-Maerki, S.; Rottmann, M.; Brun, R.; Coletta, M.; Marini, S.; Guiso, G.; Caccia, S.; Fattorusso, C., Combining 4-Aminoquinoline- and Clotrimazole-Based Pharmacophores toward Innovative and Potent Hybrid Antimalarials. J. Med. Chem. 2009, 52, 502-513.
83. Butini, S.; Gemma, S.; Campiani, G.; Franceschini, S.; Trotta, F.; Borriello, M.; Ceres, N.; Ros, S.; Coccone, S. S.; Bernetti, M.; De Angelis, M.; Brindisi, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Cagnotto, A.; Mennini, T.; Sandager-Nielsen, K.; Andreasen, J. T.; Scheel-Kruger, J.; Mikkelsen, J. D.; Fattorusso, C., Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D(3) and Serotonin 5-HT(1A) and 5-HT(2A) Receptors: Design, Synthesis, and Effects on Behavior. J. Med. Chem. 2009, 52, 151-169.
84. Butini, S.; Gabellieri, E.; Huleatt, P. B.; Campiani, G.; Franceschini, S.; Brindisi, M.; Ros, S.; Coccone, S. S.; Fiorini, I.; Novellino, E.; Giorgi, G.; Gemma, S., An Efficient Approach to Chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as Peptidomimetic Scaffolds. J. Org. Chem. 2008, 73, 8458-8468.
85. Butini, S.; Pickering, D. S.; Morelli, E.; Coccone, S. S.; Trotta, F.; De Angelis, M.; Guarino, E.; Fiorini, I.; Campiani, G.; Novellino, E.; Schousboe, A.; Christensen, J. K.; Gemma, S., 1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators. J. Med. Chem. 2008, 51, 6614-6618.
86. Butini, S.; Guarino, E.; Campiani, G.; Brindisi, M.; Coccone, S. S.; Fiorini, I.; Novellino, E.; Belinskaya, T.; Saxena, A.; Gemma, S., Tacrine based human cholinesterase inhibitors: Synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. Bioorg. Med. Chem. Lett. 2008, 18, 5213-5216.
87. Zanoli, S.; Gemma, S.; Butini, S.; Brindisi, M.; Joshi, B. P.; Campiani, G.; Fattorusso, C.; Persico, M.; Crespan, E.; Cancio, R.; Spadaria, S.; Hubscher, U.; Maga, G., Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the "primer grip" region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. Biochem. Pharmacol. 2008, 76, 156-168.
88. Butini, S.; Campiani, G.; Borriello, M.; Gemma, S.; Panico, A.; Persico, M.; Catalanotti, B.; Ros, S.; Brindisi, M.; Agnusdei, M.; Fiorini, I.; Nacci, V.; Novellino, E.; Belinskaya, T.; Saxena, A.; Fattorusso, C., Exploiting protein fluctuations at the active-site gorge of human cholinesterases: Further optimization of the design strategy to develop extremely potent inhibitors. J. Med. Chem. 2008, 51, 3154-3170.
89. Stasi, M. A.; Di Serio, S.; Vertechy, M.; Schiavone, A.; Ghirardi, O.; Minetti, P.; Campiani, G.; Borsini, F.; Carminati, P., ST2472: a new potential antipsychotic with very low liability to induce side-effects. Int. J. Neuropsychoph. 2008, 11, 309-319.
90. Verma, N. K.; Dempsey, E.; Conroy, J.; Olwell, P.; Mcelligott, A. M.; Davies, A. M.; Kelleher, D.; Butini, S.; Campiani, G.; Williams, D. C.; Zisterer, D. M.; Lawler, M.;

Volkov, Y., A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. J. Mol. Med. 2008, 86, 457-469.
91. Gemma, S.; Kukreja, G.; Tripaldi, P.; Altarelli, M.; Bernetti, M.; Franceschini, S.; Savini, L.; Campiani, G.; Fattorusso, C.; Butini, S., Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives. Tetrahedron Lett. 2008, 49, 2074-2077.
92. Fattorusso, C.; Campiani, G.; Kukreja, G.; Persico, M.; Butini, S.; Romano, M. P.; Altarelli, M.; Rost, S.; Brindisi, M.; Savini, L.; Novellino, E.; Nacci, V.; Fattorusso, E.; Parapini, S.; Basilico, N.; Taramelli, D.; Yardley, V.; Croft, S.; Borriello, M.; Gemma, S., Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents. J. Med. Chem. 2008, 51, 1333-1343.
93. Gemma, S.; Campiani, G.; Butini, S.; Kukreja, G.; Coccone, S. S.; Joshi, B. P.; Persico, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Fattorusso, E.; Taglialatela-Scafati, O.; Savini, L.; Taramelli, D.; Basilico, N.; Parapini, S.; Morace, G.; Yardley, V.; Croft, S.; Coletta, M.; Marini, S.; Fattorusso, C., Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: Design, synthesis, and biological and structure-activity relationship studies. J. Med. Chem. 2008, 51, 1278-1294.
94. Greene, L. M.; Campiani, G.; Lawler, M.; Williams, D. C.; Zisterer, D. M., BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol. Pharmacol. 2008, 73, 419-430.

SCIENTIFIC PUBLICATIONS LIST (2004-2007)

1. Gemma, S.; Kukreja, G.; Campiani, G.; Butini, S.; Bernetti, M.; Joshi, B. P.; Savini, L.; Basifico, N.; Taramelli, D.; Yardley, V.; Bertamino, A.; Novellino, E.; Persico, M.; Catalanotti, B.; Fattorusso, C., Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistan P-falciparum strains. Synthesis and molecular modeling. Bioorg. Med. Chem. Lett. 2007, 17, 3535-3539.

2. Greene, L. M.; Kelly, L.; Onnis, V.; Campiani, G.; Lawler, M.; Williams, D. C.; Zisterer, D. M., STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J. Pharmacol. Exp. Ther. 2007, 321, 288-297.

3. Gemma, S.; Campiani, G.; Butini, S.; Kukreja, G.; Joshi, B. P.; Persico, M.; Catalanotti, B.; Novellino, E.; Fattorusso, E.; Nacci, V.; Savini, L.; Taramelli, D.; Basilico, N.; Morace, G.; Yardley, V.; Fattorusso, C., Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: Exploring an innovative pharmacophore. J. Med. Chem. 2007, 50, 595-598.

4. Fattorusso, C.; Campiani, G.; Catalanotti, B.; Persico, M.; Basilico, N.; Parapini, S.; Taramelli, D.; Campagnuolo, C.; Fattorusso, E.; Romano, A.; Taglialatela-Scafati, O., Endoperoxide derivatives from marine organisms: 1,2-dioxanes of the plakortin family as novel antimalarial agents. J. Med. Chem. 2006, 49, 7088-7094.

5. Gemma, S.; Kukreja, G.; Fattorusso, C.; Persico, M.; Romano, M. P.; Altarelli, M.; Savini, L.; Campiani, G.; Fattorusso, E.; Basilico, N.; Taramelli, D.; Yardley, V.; Butini, S., Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P-falciparum strains. Bioorg. Med. Chem. Lett. 2006, 16, 5384-5388.

6. Kukreja, G.; Campiani, G.; Khurana, J. M.; Joshi, B. P.; Grover, S. K., Unexpected formation of hydroxybiphenylmethane derivatives and some new observations on Labat test. Nat. Prod. Res. 2006, 20, 1150-1154.

7. McGrath, L. B.; Onnis, V.; Campiani, G.; Williams, D. C.; Zisterer, D. M.; Mc Gee, M. M., Caspase-activated DNase (CAD)-independent oligonucleosomal DNA fragmentation in chronic myeloid leukaemia cells; a requirement for serine protease and Mn2+-dependent acidic endonuclease activity. Apoptosis 2006, 11, 1473-1487.

8. Mulligan, J. M.; Greene, L. M.; Cloonan, S.; Mc Gee, M. M.; Onnis, V.; Campiani, G.; Fattorusso, C.; Lawler, M.; Williams, D. C.; Zisterer, D. M., Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mol. Pharmacol.

2006, 70, 60-70.

9. Gemma, S.; Gabellieri, E.; Huleatt, P.; Fattorusso, C.; Borriello, M.; Catalanotti, B.; Butini, S.; De Angelis, M.; Novellino, E.; Nacci, V.; Belinskaya, T.; Saxena, A.; Campiani, G., Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J. Med. Chem. 2006, 49, 3421-3425.

10. Colletier, J. P.; Sanson, B.; Nachon, F.; Gabellieri, E.; Fattorusso, C.; Campiani, G.; Weik, M., Conformational flexibility in the peripheral site of Torpedo californica acetylcholinesterase revealed by the complex structure with a bifunctional inhibitor. J. Am. Chem. Soc. 2006, 128, 4526-4527.

11. Fattorusso, C.; Gemma, S.; Butini, S.; Huleatt, P.; Catalanotti, B.; Persico, M.; De Angelis, M.; Fiorini, I.; Nacci, V.; Ramunno, A.; Rodriquez, M.; Greco, G.; Novellino, E.; Bergamini, A.; Marini, S.; Coletta, M.; Maga, G.; Spadari, S.; Campiani, G., Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J. Med. Chem. 2005, 48, 7153-7165.

12. Greene, L. M.; Fleeton, M.; Mulligan, J.; Gowda, C.; Sheahan, B. J.; Atkins, G. J.; Campiani, G.; Nacci, V.; Lawler, M.; Williams, D. C.; Zisterer, D. M., The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo. Oncol. Rep. 2005, 14, 1357-1363.

13. Frandsen, A.; Pickering, D. S.; Vestergaard, B.; Kasper, C.; Nielsen, B. B.; Greenwood, J. R.; Campiani, G.; Fattorusso, C.; Gajhede, M.; Schousboe, A.; Kastrup, J. S., Agonist binding, efficacy and domain closure of GluR2. J. Neurochem. 2005, 94, 114-114;

14. Maga, G.; Gemma, S.; Fattorusso, C.; Locatelli, G. A.; Butini, S.; Persico, M.; Kukreja, G.; Romano, M. P.; Chiasserini, L.; Savini, L.; Novellino, E.; Nacci, V.; Spadari, S.; Campiani, G., Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective competitive nucleotide-mimicking inhibitor QU663. Biochemistry 2005, 44, 9637-9644.

15. Mc Gee, M. M.; Gemma, S.; Butini, S.; Ramunno, A.; Zisterer, D. M.; Fattorusso, C.; Catalanotti, B.; Kukreja, G.; Fiorini, I.; Pisano, C.; Cucco, C.; Novellino, E.; Nacci, V.; Williams, D. C.; Campiani, G., Pyrrolo[1,5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target. J. Med. Chem. 2005, 48, 4367-4377.

16. Campiani, G.; Butini, S.; Fattorusso, C.; Trotta, F.; Gemma, S.; Catalanotti, B.; Nacci, V.; Fiorini, I.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Stasi, M. A.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P., Novel atypical antipsychotic agents: Rational design, an efficient palladium-catalyzed route, and pharmacological studies. J. Med. Chem. 2005, 48, 1705-1708.

17. Campiani, G.; Fattorusso, C.; Butini, S.; Gaeta, A.; Agnusdei, M.; Gemma, S.; Persico, M.; Catalanotti, B.; Savini, L.; Nacci, V.; Novellino, E.; Holloway, H. W.; Greig, N. H.; Belinskaya, T.; Fedorko, J. M.; Saxena, A., Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. J. Med. Chem. 2005, 48, 1919-1929.

18. Frandsen, A.; Pickering, D. S.; Vestergaard, B.; Kasper, C.; Nielsen, B. B.; Greenwood, J. R.; Campiani, G.; Fattorusso, C.; Gajhede, M.; Schousboe, A.; Kastrup, J. S., Tyr702 is an important determinant of agonist binding and domain closure of the ligand-binding core of GluR2. Mol. Pharmacol. 2005, 67, 703-713.

19. Rogers, A.; Schmuck, G.; Scholz, G.; Griffiths, R.; Meredith, C.; Schousboe, A.; Campiani, G.; Williams, D. C., Improvements in an in-vitro assay for excitotoxicity by measurement of early gene (c-fos mRNA) levels. Arch. Toxicol. 2005, 79, 129-139.

20. Lloyd, D. G.; Hughes, R. B.; Zisterer, D. M.; Williams, D. C.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Meegan, M. J., Benzoxepin-derived estrogen receptor modulators: A novel molecular scaffold for the estrogen receptor. J. Med. Chem. 2004, 47, 5612-5615.

21. Mc Gee, M. M.; Greene, L. M.; Ledwidge, S.; Campiani, G.; Nacci, V.; Lawler, M.; Williams, D. C.; Zisterer, D. M., Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[{dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in leukemia cells occurs via the c-jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-(XL). J. Pharmacol. Exp. Ther. 2004, 310, 1084-1095.

22. Locatelli, G. A.; Campiani, G.; Cancio, R.; Morelli, E.; Ramunno, A.; Gernma, S.; Hubscher, U.; Spadari, S.; Maga, G., Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex. Antimicrob. Agents Chemother. 2004, 48, 1570-1580.

23. De Angelis, M.; Campiani, G., An efficient approach to D-threo-3-hydroxyaspartic acid for the synthesis of novel L-threo-oxazolines as selective blockers of glutamate reversed uptake. Tetrahedron Lett. 2004, 45, 2355-2357.

24. Campiani, G.; Butini, S.; Fattorusso, C.; Catalanotti, B.; Gemma, S.; Nacci, V.; Morelli, E.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Carli, M.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Vertechy, M.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P., Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J. Med. Chem. 2004, 47, 143-157.

Il sottoscritto autorizza il trattamento dei dati personali comunicati unicamente per gli adempimenti relativi all'avviso pubblico e rilasciati ai sensi del "Codice in materia di protezione dei dati personali" D.lgs n. 196/2003.

Giuseppe Campiani

Ai sensi degli artt. 46 e 47 del D.P.R. n. 445/2000 e consapevole delle responsabilità e delle sanzioni penali previste dal successivo art. 76 del medesimo decreto per false attestazioni e dichiarazioni mendaci, sotto la propria personale responsabilità, D I C H I A R A la veridicita' delle informazioni fornite.

Giuseppe Campiani

Siena 7 Gennaio 2024